Upgrade to SI Premium - Free Trial

Leerink Partners on Abbott Labs (ABT): U.S. MedTech softness could be viewed unfavorably

April 16, 2026 11:57 AM
Leerink Partners analyst Mike Kratky reiterated a Market Perform rating and $119.00 price target on Abbott Labs (NYSE: ABT)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments